An expert discusses the evolving role of bispecific antibodies in multiple myeloma, highlighting their off-the-shelf availability, immune-targeting mechanism, and growing potential in relapsed and frontline settings, while emphasizing the need for proactive toxicity management, personalized supportive care, and strategic integration into broader treatment plans.
An expert discusses the operational and financial complexities of integrating bispecific antibodies into multiple myeloma treatment pathways, emphasizing the need for standardized protocols, multidisciplinary training, payer-provider collaboration, and infrastructure investments to support safe, scalable, and value-based delivery of care.
An expert discusses the approval of a third bispecific antibody for relapsed/refractory multiple myeloma (R/R MM), highlighting its potential to reshape treatment pathways, intensify payer scrutiny around formulary positioning and cost-effectiveness, and drive a more competitive, real-world reassessment of the bispecific therapy class.
An expert discusses the growing importance of real-world evidence in informing payer decisions and value-based care strategies for bispecific therapies in relapsed/refractory multiple myeloma (R/R MM), highlighting the need to validate clinical trial outcomes, assess economic impact, and ensure equitable integration into treatment pathways.
An expert discusses how treatment guidelines and institutional pathways are evolving to integrate CAR T-cell therapies and bispecific antibodies for relapsed/refractory multiple myeloma (R/R MM), emphasizing individualized sequencing decisions, logistical considerations, and the critical role of patient and caregiver education in optimizing outcomes with bispecific therapy
An expert discusses the evolving role of BCMA-targeted therapies in relapsed/refractory multiple myeloma (R/R MM), comparing the efficacy, safety, and logistical considerations of CAR T-cell therapies, bispecific antibodies, and antibody-drug conjugates, and emphasizing the importance of individualized treatment selection and ongoing refinement of therapeutic sequencing.
An expert discusses how bispecific antibodies are reshaping the treatment landscape for relapsed/refractory multiple myeloma (R/R MM) by offering off-the-shelf, effective alternatives to CAR T-cell therapy, while emphasizing the need for institutional planning, patient monitoring, and coordinated care to manage continuous therapy, adverse effects, and resource demands.
Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, looks to the future of myelofibrosis treatment and discusses ongoing research and the evolving therapeutic landscape.
Addressing financial toxicity associated with myelofibrosis treatment, Dr Mahmoudjafari discusses cost considerations and how lower WAC products can benefit patients.
Dr Mahmoudjafari shares clinical strategies for optimizing patient outcomes and reducing the rate of adverse events and treatment discontinuations.
A clinical pharmacy manager provides insights on optimal patient monitoring practices for patients receiving treatment for myelofibrosis.
Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, outlines factors that inform treatment decisions for patients with myelofibrosis, including comorbidities and platelet count.
Dr Mahmoudjafari provides an overview of JAK inhibitors available for the treatment of patients with myelofibrosis.
Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, shares expert perspectives on the important role of risk stratification in determining optimal treatment decisions for patients with low-risk or high-risk myelofibrosis.
An expert on myelofibrosis provides clinical insights on features of the disease that can impact patient quality of life, including splenomegaly, hypertension, and bone pain.
A clinical pharmacy manager discusses challenges frequently encountered in the treatment of patients with myelofibrosis.
Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, provides an overview of myelofibrosis, covering its incidence and prevalence in the United States as well as patient presentation and prognosis.
Published: August 14th 2024 | Updated:
